Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 4NETWORK 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Biphenotypic, Acute 6Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lung Neoplasms 4Burkitt Lymphoma 4Wilms Tumor 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Ganglioneuroblastoma 3Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hepatoblastoma 2Hematologic Neoplasms 2Fibrolamellar hepatocellular carcinoma 2Desmoid Tumors 2Carcinoma, Embryonal 2Anatomic Stage I Breast Cancer AJCC v8 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1

Interventions

Radiotherapy 9Vincristine 8Dactinomycin 8Cyclophosphamide 8Ifosfamide 6Radiation 5Filgrastim 5Doxorubicin 5Irinotecan 4sargramostim 3pegfilgrastim 2brostallicin 2Vinorelbine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trioctyl phosphine oxide 1perifosine 1lorvotuzumab mertansine 1irinotecan sucrosofate 1imetelstat 1exatecan 1etoposide phosphate 1X-Rays 1Trabectedin 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Rhabdomyosarcoma × Specimen Handling × Clear all
NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Active not recruiting
118 enrolled
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡